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Abstract
Background: Protective responses against Mycobacterium tuberculosis are dependent on appropriate T cell and
macrophage activation. Mycobacterial antigen six kDa early secreted antigenic target (ESAT6) and culture filtrate protein
10 (CFP10) can detect M. tuberculosis specific IFNc responses. However, most studies have been performed in non-endemic
regions and to study pulmonary tuberculosis (PTB). We have studied ESAT6 and CFP10 induced cytokine and chemokines
responses in PTB and extrapulmonary (EPul) TB.
Methodology: IFNc, IL10, CXCL9 and CCL2 responses were determined using an ex vivo whole blood assay system in PTB
(n = 30) and EPulTB patients with limited (LNTB, n = 24) or severe (SevTB, n = 22) disease, and in healthy endemic controls
(ECs). Responses to bacterial LPS were also determined.
Principal Findings: ESAT6- and CFP10-induced IFNc was comparable between ECs and TB patients. Both ESAT6- and CFP10-
induced IFNc secretion was greater in LNTB than PTB. ESAT6-induced CXCL9 was greater in EPulTB as compared with PTB,
with an increase in SevTB as compared with LNTB. CFP10-induced CCL2 was higher in PTB than LNTB patients. LPS-
stimulated CXCL9 was greatest in SevTB and LPS-induced CCL2 was increased in PTB as compared with LNTB patients. A
positive correlation between ESAT6-induced IFNc and CXCL9 was present in all TB patients, but IFNc and CCL2 was only
correlated in LNTB. ESAT-induced CCL2 and CXCL9 were significantly associated in LNTB while correlation in response to LPS
was only present in SevTB.
Conclusions: ESAT6 induced IFNc and CXCL9 can differentiate between limited and severe TB infections.
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Introduction
Protective immunity against Mycobacterium tuberculosis is depen-
dent on the interplay between activated T cells, macrophages and
other leucocytes, proinflammatory cytokines such as, interferon
gamma (IFNc), tumor necrosis factor-alpha (TNFa) and interleu-
kin (IL)-12, and down-modulatory cytokines IL-10 and transform-
ing growth factor beta (TGF)-b [1,2]. IL10 produced by
macrophages is important in regulating the Th1 cytokine balance
and down regulates proinflammatory responses [3]. TNFa
regulated granuloma formation relies on effective recruitment of
leucocytes, dependent on chemokines such as the CC chemokines;
CCL2, CCL3, CCL4, CCL5 and CXC chemokines; CXCL8,
CXCL9 and CXCL10 [4–7]. Coordinate expression of these
chemokines with their receptors is essential for granuloma
formation. Deficiency of the CCL2 receptor, CCR2, has been
shown to result in progressive infection by M. tuberculosis in mice
[8]. CXCL9 stimulates T lymphocytes [9] and has previously been
shown to be a sensitive predictive marker for antigen-specific IFNc
production and IFNc secreting cells [10].
Rapid diagnosis of tuberculosis (TB) infections is essential for
early detection and control of disease. Six kDa early secreted
antigenic target (ESAT6) and culture filtrate protein 10 (CFP10)
are both encoded by the region of difference 1 (RD1) which is
present in M. tuberculosis and M. bovis, but absent from M. bovis
BCG and most environmental mycobacteria [11,12]. ESAT6 is a
immunodominant T cell-stimulatory antigen and is recognized by
specific IFNc-secreting T cells present in greater numbers in
patients with active disease as compared with those who are un-
infected [13,14]. Commercial tests employing IFNc release assays
(IGRA) such as, ESAT6 Quantiferon TB-2G [15,16] and T-
SPOT TB are increasingly available as diagnostic and predictive
tests for vaccination. Therefore, ESAT6 and CFP10 induced IFNc
responses have been shown to be useful in discriminating infected
individuals from healthy controls [17–19]. However, there are
controversial reports from endemic regions. In TB endemic
regions, IFNc can be modulated by natural exposure to M.
tuberculosis or non-tuberculous mycobacteria as well as BCG
vaccination [20,21]. Recent studies have shown that the sensitivity
of IGRA may be related to the ethnic origin and age of the
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individual tested [22]. The sensitivity of ESAT6 and CFP10
induced Mycobacterium-specific T cell responses is greatest in a
BCG unvaccinated population in a non-endemic region and
most studies have been performed in areas of low tuberculosis
(TB) transmission [23], with less data available from high
transmission TB endemic regions [24]. A recent study has
shown that the utility of using additional biomarkers such as
CCL2 and CXCL10 together with IFNc to assess mycobacterial
antigen induced responses in identifying patients with M.
tuberculosis infection [25]. However, most research has been
performed on patients with pulmonary tuberculosis (PTB).
Although PTB is the predominant form of tuberculosis, extra-
pulmonary disease (EPulTB) involving; lymph nodes, skeletal
system, abdomen, meningeal, miliary or disseminated forms of
the disease remain common [26,27]. EPulTB presents an
additional burden due to the problems associated with diagnosis
and treatment of infections in extra-pulmonary sites. It is
therefore essential to assess IFNc induced responses to
mycobacterial antigens in endemic areas and in patients with
PTB and EPulTB. This work has been carried out in Pakistan
which is ranked 8th amongst high TB burden countries and has
an incidence of 181/100,000 cases/year, where 44% pulmonary
and 15% extrapulmonary samples are listed under new case
detection for DOTS [28].
The ex vivo whole blood assay model is useful in assessing host
immune responses in tuberculosis patients [29] [30], despite its
limitations in identifying the cellular sources of secreted products.
We have investigated mycobacterium specific responses using
antigens ESAT6 and CFP10 and also response to bacterial
lipopolysaccharide (LPS) in whole blood cultures of patients with
PTB (n= 30) and EPulTB (n= 46) with differing disease severity.
Cytokines (IFNc and IL10) and chemokines (CXCL9 and CCL2)
were measured in each donor. Our results indicate that ESAT6-
induced IFNc and CXCL9 responses do not discriminate between
active TB patients and healthy endemic controls (ECs), but that
they do differentiate severity of infections.
Results
Characteristics of study group
Table 1 illustrates hematological characteristics of patients in
the study. EPulTB patients were divided according to WHO
ranking of severity into less severe TB (LNTB) or severe TB
(SevTB) [28], see methods and Table 2. The study groups were
comparable with respect to age and gender. As expected [27],
erythrocyte sedimentation rate (ESR) was found to be raised in TB
patients as compared with ECs; PTB, LNTB and SevTB (p,0.01,
0.01, 0.01, respectively). Total leucocyte (TLC) and monocyte
counts were comparable between patients and controls. However,
in PTB and SevTB, lymphocyte counts were decreased (p = 0.002,
p,0.01, respectively), while neutrophil counts were increased
(p = 0.02, p= 0.008, respectively).
Cytokine and chemokine secretion in unstimulated
whole blood cultures of TB patients and endemic
controls
IFNc, IL10 and CXCL9 and CCL2 secretion from unstimu-
lated cells was measured in healthy endemic controls (ECs, n= 17)
and in TB patients (n = 76, Table 3). IFNc, IL10 and CCL2
secretion from unstimulated whole blood cells of ECs and TB
patients were comparable. However, CXCL9 secretion from
unstimulated whole blood cells of ECs was greater than in TB
patients (p = 0.031).
Mycobacterial antigens ESAT6-induced IFNc, IL10, CCL2
and CXCL9 in TB patients
ESAT6–induced cytokine and chemokines responses were
determined in whole blood cells of 76 TB patients. Upon
stimulation by ESAT6, the trend of IFNc secretion at 5 day
post-stimulation was greater in TB patients as compared with ECs
but did not achieve statistical significance (Table 3). ESAT6-
induced IL10 secretion was also increased in TB patients but was
not statistically significant as compared with ECs (p = 0.07).
CXCL9 has been shown to be induced by ESAT6 in patients
with pulmonary TB [17]. We found ESAT6-induced CXCL9 to
be significantly greater in TB patients as compared with ECs
(p = 0.003). While, no difference was observed between ESAT6-
induced CCL2 in TB patients and ECs.
CFP-10 induced cytokine and chemokine responses
We also compared CFP10 induced whole blood cell responses in
ECs and TB patients. CFP10-induced IFNc was increased in TB as
compared with ECs but was not significantly different (Table 3).
CFP10-induced IL10 (p=0.002) secretion and also CXCL9
(p=0.001) secretion was significantly raised in TB patients. However,
there was no difference in CFP10-induced CCL2 between patients
and controls. Although the trend of responses to ESAT6 and CFP10
were comparable, the magnitude of cytokine responses to CFP10 was
approximately 2 fold greater than that induced by ESAT6.
LPS-induced cytokine and chemokine secretion in TB
patients
To investigate whether the differences in cytokine secretion
observed were specific to mycobacterial antigens, we also studied
cytokine and chemokine responses to bacterial lipopolysaccharide
(LPS), a strong activator of macrophages. LPS-induced IL10 was not
different between TB patients and ECs, Table 3. However, LPS-
induced CXCL9 was significantly greater (p=0.008), while CCL2
was reduced (p,0.01) in TB patients as compared with ECs.
Differential ESAT6-induced IFNc in pulmonary and
extrapulmonary TB
We further investigated IFNc responses to mycobacterial
antigens in TB patients with pulmonary and extrapulmonary
disease of differing severity. Pulmonary TB patients included in
Table 1. Characteristics of tuberculosis patients and healthy
endemic controls.
Characteristic EC PTB LNTB SevTB
Number 17 30 24 22
Age (y) 27.565.9 27.8612.2 33.2612.4 36.68618.7
Male:Female 9 vs 8 11 vs 19 9 vs 15 10 vs 12
ESR (mm/h) 5.462.9 54637* 34.4625.2* 45.4633.8*
Hb (g/dL) 13.661.1 11.861.8* 12.361.6* 12.261.5*
TLC (10e9/L) 7.461.6 9.465.1 7.762.3 8.162.8
Lymphocytes
(10e9/L)
2.360.5 1.760.7* 2.060.7 1.360.4*
Monocytes (10e8/L) 5.361.6 6.062.8 5.862.4 4.761.7
Neutrophils (10e9/L) 4.361.2 7.064.7* 5.062.0 6.062.7*
EC, healthy endemic controls; PTB, pulmonary TB; LNTB, limited extrapulmonary
TB; SevTB, severe extrapulmonary TB.
*denotes significant difference (p,0.05) as compared with EC.
doi:10.1371/journal.pone.0005158.t001
Chemokines in Tuberculosis
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Table 2. Diagnostic criteria for patients with severe extrapulmonary tuberculosis.
No. Site of tuberculosis Abscess Microscopya Radiologyb AFBCc Histopathologyd
1 Spine Yes Yes Positive
2 Spine Yes Yes Negative Positive
3 Spine Yes Yes
4 Spine Yes Yes Positive Positive
5 Spine Yes Yes
6 Spine Yes Yes
7 Spine Yes Yes
8 Spine Negative Yes Positive Positive
9 Spine Yes Positive Positive
10 Meningese Yes Negative
11 Meningese Yes Negative
12 Meninges Positive Yes Positive Positive
13 Meninges Positive Yes Positive
14 Meningese Negative Yes Negative
15 Meningese Positive
16 Abdomen Positive Yes Negative
17 Abdomen Negative Positive
18 Abdomen Yes Negative
19 Miliary Yes Negative Positive
20 Intestines Yes Positive
21 Bilateral Pleural Negative Yes Negative Positive
22 Bilateral Pleural Yes
aindicates acid fast bacilli staining of smears.
bincludes Xray, MRI or CT imaging characteristic of tuberculosis.
cacid fast bacilli culture using BACTEC radiometric assay, Becton Dickinson, USA.
dbiopsy results indicate caseating or necrotic granulomatous inflammation indicative of M. tuberculosis infection.
eshowed a favorable clinical response to anti-tuberculous treatment.
doi:10.1371/journal.pone.0005158.t002
Table 3. ESAT6- and CFP10-induced cytokine and chemokine responses.
Unstimulated cells
Group (n) IFNc (Mean6SD pg/ml) IL10 (Mean6SD (pg/ml) CXCL9 (Mean6SD pg/ml) CCL2 (Mean6SD pg/ml)
EC (17) 2.062.8 136.86287 7.9620.2 866327
TB (76) 6.3613 10.8617.9 2.3618.8* 90.46334
ESAT6-induced responses
Group (n) dIFNc (Mean6SD pg/ml) dIL10 (Mean6SD (pg/ml) dCXCL9 (Mean6SD pg/ml) dCCL2 (Mean6SD pg/ml)
EC (17) 29646 12636 1.766.5 145661300
TB (76) 2996520 936225 1236278* 11976843
CFP-induced responses
Group (n) dIFNc (Mean6SD pg/ml) dIL10 (Mean6SD (pg/ml) dCXCL9 (Mean6SD pg/ml) dCCL2 (Mean6SD pg/ml
EC (17) 2866442 23.4670.2 19.6631.9 278762293
TB (64) 6356720 1556237* 79261113* 207661149
LPS-induced responses
Group (n) dIL10 (Mean6SD (pg/ml) dCXCL9 (Mean6SD pg/ml) dCCL2 (Mean6SD pg/ml
EC (17) 3426577 17.3646 353661504
TB (64) 614.46733 3906979* 192061047*
EC, healthy endemic controls; TB, tuberculosis patients.
‘d’ denotes cytokine secretion after background subtraction in each case.
*denotes significant difference (p,0.05) as compared with EC.
All statistical analyses performed using the Mann-Whitney U non-parametric test.
doi:10.1371/journal.pone.0005158.t003
Chemokines in Tuberculosis
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the study comprised those with minimal (n = 6) and moderate
(n = 24) disease. However, we found antigen stimulated IFNc
secretion in minimal and moderate PTB patients to be comparable
between groups (data not shown) and have therefore performed
further analysis on the combined minimal/ moderate PTB group.
Responses in PTB patients were compared with those of EPul-
TB; limited (LNTB) or severe (SevTB). As illustrated in Fig. 1A,
ESAT6-induced IFNc in LNTB (median, 253 pg/ml) was
significantly greater than in PTB (median, 3 pg/ml, p = 0.011).
IFNc responses in LNTB were significantly greater as compared
with SevTB (median, 1 pg/ml, p = 0.029). ESAT6-induced IL10
was negligible in all TB groups (PTB, LNTB, SevTB; 0, 3, 3 pg/
ml respectively, data not shown).
The balance between proinflammatory IFNc and downmodu-
latory IL10 has been shown to be critical in determining outcome
of mycobacterial infections [31], and the IFNc (5d) /IL10 (2d)
ratio induced in response to mycobacterial antigens has been
shown to be to be an indicator of disease severity in tuberculosis
[32]. We found the ESAT6-induced IFNc/IL10 ratio to be
significantly greater in LNTB (median, 3.5) as compared with the
SevTB group (median, 1; p = 0.011, data not shown), consistent
with these earlier reports.
ESAT6-induced CXCL9 was significantly raised in EPulTB
groups SevTB (p,0.01) and LNTB (p= 0.029) as compared with
PTB (Fig. 1B). No difference was observed between ESAT6-
induced CCL2 in whole blood cells of PTB, LNTB or SevTB
patients (median; 782, 1568 and 1056 pg/ml, respectively, data
not shown).
CFP10-induced cytokine and chemokine responses in
PTB and EPulTB
CFP10-induced IFNc was greater in LNTB as compared with
PTB patients (p = 0.044), but did not differ from with SevTB,
Fig. 2A. CFP10-induced IL10 was found to be comparable
between the TB patient groups (median; PTB, 22; LNTB, 30;
SevTB, 52 pg/ml, data not shown).
Coincident with results observed in response to ESAT6, CFP10-
induced IFNc /IL10 ratio was also greater in LNTB patients
(median, 35) as compared with those with SevTB (median, 0.1;
p = 0.001, data not shown).
No differences were observed in CFP10-induced CXCL9 in
PTB (51 pg/ml) and EPulTB groups, although CFP10 induced a
greater trend of CXCL9 secretion in LNTB and SevTB (543,
192 pg/ml, respectively, data not shown). As observed in the case
of IFNc, CFP10-induced CXCL9 was 2 fold greater in magnitude
as compared with that in response to ESAT6.
However, CFP10-induced a significantly greater CCL2 re-
sponse in PTB patients as compared with LNTB (p= 0.036,
Fig. 2B).
LPS-induced CXCL9 and CCL2 is greater in severe as
compared with limited TB
When LPS-induced CXCL9 was measured in PTB, LNTB and
SevTB groups it was observed that chemokine levels were
significantly greater in SevTB as compared with PTB and LNTB
(p= 0.001, 0.004, respectively), Fig. 3A. In contrast, LPS-induced
CCL2 was greater in PTB as compared with LNTB (p= 0.01) and
also in SevTB patients as compared with LNTB (p= 0.003),
Fig. 3B.
Relationship between CXCL9, CCL2 and IFNc secretion in
tuberculosis patients
We next determined the association between cytokine and
chemokine responses induced to mycobacterial antigen ESAT6
and to LPS in different TB patient groups. A Spearman’s rank
correlation analysis showed ESAT6-induced secretion of IFNc
and CXCL9 to be positively associated in all TB groups (Table 4).
A significant association between ESAT6-induced IFNc and
CCL2 (R= 0.471, p = 0.027) and between CCL2 and CXCL9
(R=0.57, p = 0.006) was observed only in the LNTB group, data
not shown.
Figure 1. Differential ESAT6-induced IFNc and CXCL9 in pulmonary and extrapulmonary TB. Whole blood cells were stimulated with
ESAT6 at 5 mg/ml, and IFNcmeasured in cell supernatants harvested at 5 day post-stimulation, while CXCL9 was measured at 2 days post-stimulation.
TB patient groups comprised those with pulmonary TB (PTB, n = 30), less severe EPulTB (LNTB, n = 24) and severe EPulTB (SevTB, n = 22). The box plots
represent data from each group after cytokine secretion from unstimulated cells has been subtracted. The whiskers indicate the 25th and 75th quartile
respectively, while the median line separates the two. ‘*’ denotes significant differences between groups, p,0.05; (*). A. IFNc, B. CXCL9.
doi:10.1371/journal.pone.0005158.g001
Chemokines in Tuberculosis
PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5158
No association was found between LPS-induced IL10 and either
CXCL9 or CCL2. However, LPS-induced CXCL9 and CCL2
were found to be positively associated in patients with SevTB but
not in PTB or LNTB groups (Table 4).
Discussion
The relationship between cytokines, IFNc and IL10 in
regulating the outcome of M. tuberculosis infections is well studied.
We have recently shown that circulating levels of IFNc and
CXCL9 differ in patients with pulmonary and extrapulmonary
disease [33]. We show here that the relationship between
mycobacterial antigen induced IFNc and CXCL9 may play a
role in determining disease severity in tuberculosis.
Our study illustrates that in a TB endemic region, ESAT6-
induced IFNc responses may not be as effective in distinguish-
ing patients with active disease from healthy individuals in
endemic regions. This may be attributed to immune modula-
tion of IFNc responses to specific M. tuberculosis antigens as has
been shown in a recent study of household contacts of TB
patients [31]. Also, a high rate of transmission in endemic
regions may result in modulation of IFNc and IL10 responses
due to increased exposure to environmental mycobacteria
[21,34].
Figure 2. Differential CFP10-induced IFNc and CCL2 in PTB and EPulTB. Whole blood cells from different patients were stimulated with
CFP10 at 5 mg/ml. IFNc and CCL2 were measured in cell supernatants. All other parameters as described in Fig. 1. The box plots indicate cytokine
secretion in PTB, LNTB and SevTB groups. A. IFNc, B. CCL2.
doi:10.1371/journal.pone.0005158.g002
Figure 3. Differential LPS-induced CXCL9 and CCL2 in limited and severe TB. Whole blood cells were stimulated with LPS at 1 mg/ml and
CXCL9 measured in cell supernatants harvested at 2 days post-stimulation. All other parameters as described in Fig. 1. A. CXCL9 and B. CCL2.
doi:10.1371/journal.pone.0005158.g003
Chemokines in Tuberculosis
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Amongst healthy controls we studied asymptomatic individuals
who were both TST2 and TST+. However, we did not observe
any difference between cytokine or chemokine induced responses
from whole blood cells of either group either after measurement
from unstimulated cells or from ESAT6 or CFP10 stimulated cells
(data not shown), corresponding with previous reports [35].
However, when both EC groups; TST2 and TST+ donors were
compared with TB patients, a significant differences in ESAT6-
and CFP10-induced CXCL9 and CCL2 secretion was found in
TB patients as compared with TST2 individuals but not in the
TST+ group (data not shown). This may be attributed to latent
infection in the TST+ controls which would raise specific cytokine
responses to mycobacterial antigens. Previous reports have shown
Th1-like effector memory cells to be increased in bronchoalveolar
cells from TST+ individuals as compared with TST2 individuals,
with coordinate increase in IFNc and IFNc regulated chemokines
[36]. Therefore, in our study we have compared responses of TB
patients with Ecs who are TST2 in order to have the least
exposed group as a control.
In all cases, antigen-induced IFNc secretion increased in
magnitude from 2 to 5 days post-stimulation (data not shown).
This may be attributed to the differing cellular sources of IFNc
whereby at the earlier time point there would be a greater
contribution from effector T cells, NK cells, cd T cells and
activated macrophages, while at the latter time point the IFNc
may primarily be released from mycobacterium specific T
memory cells.
We found ESAT6-induced IFNc response to be decreased in
patients with severe disseminated TB, comprising of those with
spinal, meningeal, abdominal, miliary involvement, as compared
with localised disease. Tuberculous lymphadenitis is the most
common presentation of extrapulmonary TB. It is often a self-
limiting disease and is less severe as compared with other forms.
Increased IFNc responses in less severe TB infections correlates
with previous work which has shown the frequency of antigen
specific CD4 T cells to be greater in latently infected individuals
and in those with minimal disease with a low bacterial burden as
compared with patients with a higher bacterial load [37].
Therefore, patients with limited extrapulmonary disease may be
more likely to have an increased number of IFNc secreting T cells
as compared with those with progressive disease [37]. Previous
reports haves shown that in pulmonary TB, there is a decrease in
IFNc responses related to increased severity of disease [38,39].
Our data corresponds with previous work which has shown that
differences in the severity of extrapulmonary TB can be defined by
the IFNc: IL10 ratio to mycobacterial antigens, with a direct
relationship between disseminated disease or disease localized to
peripheral sites without lung involvement [32,40].
CXCL9 is IFNc induced and has been shown to be an early
marker of IFNc activation and of T cells secreting IFNc [10].
CXCL9 is a chemotactic ligand produced by macrophages and
other antigen presenting cells at the site of inflammation [9]. We
found ESAT6-induced CXCL9 to be increased in TB patients,
corresponding with previous reports [17]. This corresponds with
reports by Gonzalez-Juarrero et al. who show upregulated
expression of IFNc regulated chemokines transcripts in response
to M. tuberculosis coordinate with inflammation in the mouse model
[41]. The increase in CXCL9 observed in severe extrapulmonary
disease corresponds with literature which have shown chemokines
responses to be increased in severe TB such as in tuberculous
meningitis [42,43]. CFP10-induced activation of CXCL9 was
greater than that observed for ESAT6 just as observed in the case
of IFNc. Although the trend of responses to ESAT6 and CFP10
was comparable, ESAT6 appeared to elicit more significant
difference in responses between limited and severe TB. This may
be due to differential recognition of cell surface receptors for the
recombinant antigens on T cells which may determine the
magnitude of IFNc response and subsequently impact macro-
phage activation.
ESAT6 stimulated secretion of induced- CCL2 was not different
between TB groups, further indicating the utility of this antigen in
eliciting T cell specific responses.
LPS is a strong stimulant of monocyte responses, and both
CXCL9 and CCL2 are produced by monocytes. Raised LPS-
induced CXCL9 in severe extrapulmonary TB may be indicative
of the increased inflammatory processes ongoing in progressive,
disseminated disease and an absence of regulation. CCL2 has
previously been shown to be increased in PTB patients as
compared with Epul-TB patients and our results with LPS support
this. In addition, we observe that as in case with CXCL9, CCL2
levels are raised in severe TB as compared with limited disease in
patients with extrapulmonary TB.
Our correlation analysis between the cytokines and chemokines
produced by whole blood cells of TB patients indicates differential
regulation of cytokines in response to mycobacterial antigen
stimulation in patients with differing disease severity. A positive
association was found between ESAT6 induced IFNc and CXCL9
in all TB patients indicating that this balance may play a predictive
role in the Th1-like cytokine balance required for protection
against M. tuberculosis. However, as association between the
macrophage activating CCL2 and the T cell activation IFNc
and CXCL9 was only found in LNTB patients. When LPS-
induced responses were investigated, there appeared to be no
association between CCL2 and CXCL9 in limited disease (PTB
and LNTB), but a correlation between these two chemokines was
present in severe extrapulmonary TB. It is possible that in severe
extrapulmonary disease where there is an overall reduction in
IFNc possibly due to T cell anergy, CXCL9 secretion may lead to
increased macrophage recruitment and inflammation, the lack of
association between the chemokines and T cell regulation may
result in progressive disease related pathology in the host. Overall,
Table 4. Correlation between cytokines and chemokines
stimulated by ESAT6 and LPS.
IFNc to CXCL9
TB group
PTB LNTB SevTB
ESAT6
R 0.583* 0.508* 0.577*
p-value 0.001 0.016 0.015
CXCL9 to CCL2
TB group
PTB LNTB SevTB
LPS
R 20.073 0.16 0.689**
p-value 0.789 0.569 0.006
EC, endemic controls; PTB, pulmonary TB; LNTB, less severe EPul-TB; SevTB,
severe EPul-TB.
R values 0.4–0.6 indicate a moderate positive association.
*while 0.6–0.8 indicate a strong positive association
**p value#0.05 are significantly different.
doi:10.1371/journal.pone.0005158.t004
Chemokines in Tuberculosis
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this work proposes differential chemokine regulation in limited and
severe tuberculosis infections which may explain subsequent
pathophysiological changes in the host. Further investigations into
the mechanisms responsible for the control of macrophage
activation in different disease states may further explain this
phenomenon.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Aga Khan University hospitals. All
patients provided written informed consent for the collection of
samples and subsequent analysis.
Subject selection
Seventy six patients were recruited from the Aga Khan
University Hospital and Medical College (AKUH) and Masoom-
een Hospital, Karachi. All study subjects were examined and
evaluated by infectious diseases consultants. Patients were newly
diagnosed or had taken less than 7 days of anti-tuberculous
therapy (ATT). Patients with significant co-morbid conditions
including diabetes mellitus, chronic renal failure, chronic liver
disease, patients on high dose corticosteroid therapy were excluded
to assure relatively unmodulated immunological parameters. All
patients were tested and found to be HIV negative.
Patients with pulmonary TB (PTB, n= 30) were diagnosed by
clinical examination, chest X-ray, sputum acid fast bacillus (AFB)
Zeihl Neelson staining, AFB culture and/ or clinical response to
treatment (along with fever, cough and weight loss). All PTB
patients had findings consistent with active TB as evaluated by one
of the consulting physicians. Fifteen patients were found to have a
positive AFB smear microscopy. Nine PTB patients had an AFB
negative smear, but showed a favourable clinical response to ATT.
Patients were diagnosed as having minimal, moderate or advanced
pulmonary tuberculosis using a modified classification of the
National Tuberculosis Association of the USA based on extent of
lung tissue involvement [44,45]. Of the PTB patients 6 had
minimal, while 24 had moderate disease.
Diagnosis of TB lymphadenitis, spinal, abdominal and genito-
urinary TB was based on histopathological findings of chronic
granulomatous inflammation with caseous necrosis, AFB staining
and culture and supportive radiological evidence on CT or MRI.
Diagnosis of meningeal TB was based on CSF biochemical
findings, supported by AFB culture and findings on contrast-
enhanced CT and/or MRI. Pleural TB was diagnosed on the basis
of pleural fluid biochemical findings, AFB culture, histopatholog-
ical findings on pleural biopsy and supportive radiological
evidence on X-rays and/or contrast-enhanced CT scan
Patients with extrapulmonary TB (Epul-TB) were divided into
two groups according to the WHO ranking of diseases severity
based on bacillary load, extent of disease and anatomical site [28].
Epul-TB patients were subsequently classified into less severe
(LNTB) or severe (SevTB) disease. Of the 24 patients with LNTB,
23 had lymphadenitis and 1 had genitourinary TB. All LNTB
patients were confirmed on histological findings consistent with
tuberculosis. Twenty two patients had SevTB and their diagnostic
criteria are provided in Table 2.
BCG-vaccinated asymptomatic healthy volunteers who were
staff at AKU with no known exposure to TB were used as endemic
controls (Ecs). All volunteers had a normal chest X-Ray.
Tuberculin skin testing (TST) was assessed by administering five
tuberculin units on the volar surface of the right arm subcutane-
ously, and read by a single reader at 48 h. An induration of
$10 mm was used as a cutoff for positive responses and TST2
(n = 17) Ecs were included in the study.
Reagents
Recombinant antigens ESAT6 and CFP10 were provided
through the TB Vaccine Testing and Research Materials
Contract, NIH, NIAID NO1-A1-40091, awarded to Colorado
State University, USA.
Whole blood assay
Venous blood was diluted 1:10 in RPMI-1640 medium and
200 ml set up per well in a 96 well tissue culture plate as described
previously [29]. Whole blood cells were stimulated with recom-
binant antigens ESAT-6 (5 mg/ml) and CFP-10 (5 mg/ml) and
cultured for up to 5 days. All samples were set up in replicates.
Supernatants were collected at 2 and 5 day post-stimulation for
cytokine and chemokine measurements. Samples were centrifuged
to collect any cellular debris, aliquoted and stored at –70 C until
tested. Cytokines were measured at both 2 and 5 days post-
stimulation. We have presented IFNc responses from whole blood
cells at 5 day of culture to focus on T cell responses [21,29]. IL10
increased only marginally from 2 to 5 day post-stimulation and
there was no significant increase between the two times studied
(data not shown). Therefore, we have further analyzed IL10
responses at 2 day post-stimulation. CCL2 and CXCL9 were
optimally measured at 2 days post-stimulation.
ELISA for IFNc, IL-10 and CXCL9
IFNc and IL-10 was detected in cellular supernatants by using
standards and ELISA reagents obtained from Endogen (Rockford,
IL, USA). Cytokines were measured using a sandwich ELISA
technique according to the manufacturer’s instructions and as
reported previously [30]. Recombinant human cytokine was used
to obtain a dose response curve with a range of detection from
3.9–1000 pg/ml. All experimental samples were tested in
duplicate.
CXCL9 and CCL2 standards and monoclonal antibody pairs
for capture and detection were obtained from R&D Systems
(Abingdon, UK). All measurements were carried out according to
the manufacturer’s recommendations and as described previously
[30]. Recombinant human cytokine was used to obtain a dose
response curve with a range of detection from 6.25–500 pg/ml for
CXCL9 and 6.25–1000 pg/ml for CCL2.
Statistical analysis
Data is represented by box blots illustrating 25th and 75th
quartiles with the median shown as a horizontal bar. Non-
parametric statistical analysis was performed using Kruskal-Wallis
and Mann-Whitney U tests as required. P values#0.05 were
considered to be statistically significant. Spearman’s Rank
Correlation was also performed, all using the Statistical Package
for Social Sciences software (SPSS).
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